Antifungal Susceptibility of Oral Candida Isolates from Mother-Infant Dyads to Nystatin, Fluconazole, and Caspofungin

• Published in: Journal of fungi (Basel) Vol. 9; no. 5; p. 580
• Main Authors: Alkhars, Naemah, Gaca, Anthony, Zeng, Yan, Al-Jallad, Nisreen, Rustchenko, Elena, Wu, Tong Tong, Eliav, Eli, Xiao, Jin
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 17.05.2023; MDPI
• Subjects: antifungal agent; Antifungal agents; Biofilms; Candida; Caspofungin; CDR2 gene; Children; Children & youth; Clinical isolates; Complementarity-determining region 1; Dental caries; Drugs; Enzymes; Fluconazole; Fungi; Genomes; in vitro susceptibility; Infants; Laboratories; MDR1 protein; Minimum inhibitory concentration; Missense mutation; Mothers; Mutation; Nystatin; oral Candida; Susceptibility; Whole genome sequencing; Yeast; United States > US; antifungal agent; fluconazole; in vitro susceptibility; oral Candida; nystatin; caspofungin
• ISSN: 2309-608X; 2309-608X
• DOI: 10.3390/jof9050580

The carriage of in children's oral cavities is associated with a higher risk for early childhood caries, so controlling this fungus in early life is essential for preventing caries. In a prospective cohort of 41 mothers and their children from 0 to 2 years of age, this study addressed four main objectives: (1) Evaluate in vitro the antifungal agent susceptibility of oral isolates from the mother-child cohort; (2) compare susceptibility between isolates from the mothers and children; (3) assess longitudinal changes in the susceptibility of the isolates collected between 0 and 2 years; and (4) detect mutations in antifungal resistance genes. Susceptibility to antifungal medications was tested by in vitro broth microdilution and expressed as the minimal inhibitory concentration (MIC). clinical isolates were sequenced by whole genome sequencing, and the genes related to antifungal resistance, , , , , , and , were assessed. Four spp. (n = 126) were isolated: , and . Caspofungin was the most active drug for oral , followed by fluconazole and nystatin. Two missense mutations in the gene were shared among isolates resistant to nystatin. Most of the children's isolates had MIC values similar to those from their mothers, and 70% remained stable on antifungal medications from 0 to 2 years. For caspofungin, 29% of the children's isolates showed an increase in MIC values from 0 to 2 years. Results of the longitudinal cohort indicated that clinically used oral nystatin was ineffective in reducing the carriage of in children; novel antifungal regimens in infants are needed for better oral yeast control.